Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Nutt

Showing results (41-50 of 179) with videos related to

Pageof 18
Sort By:
Acta Neuropsychiatrica|March 8, 2019
Antidepressants; what's the beef?Guy M Goodwin, David Nutt
Lancet (London, England)|July 31, 2007
Seizures in a night clubLeslie A King, David Nutt
Journal of Psychopharmacology (Oxford, England)|October 26, 2018
THuNDRous news for human dopamine researchers: A selective dopamine D1 receptor antagonist will soon be available for clinical researchDavid Nutt, Trevor Robbins, Ann Hayes
Current Pharmaceutical Design|May 29, 2012
Neuroimaging of serotonin system in anxiety disordersEduard Maron, David Nutt, Jakov Shlik
Neuropharmacology|September 30, 2022
Psychedelics therapeutics: What we know, what we think, and what we need to researchDavid Nutt, Meg Spriggs, David Erritzoe
Neuropharmacology|November 13, 2012
Pharmacological cognitive enhancement in healthy people: potential and concernsSteve Hyman, Nora Volkow, David Nutt
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 11, 2014
The extinction of drugs for clinical research: Can the ECNP medicines chest save them?David Nutt, Gavin Kilpatrick, Ann Hayes
Frontiers in Psychiatry|April 6, 2019
A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted PsychotherapyBen Sessa, Laurie Higbed, David Nutt
Dialogues in Clinical Neuroscience|November 5, 2008
Sleep disorders as core symptoms of depressionDavid Nutt, Sue Wilson, Louise Paterson
Addiction (Abingdon, England)|June 9, 2018
Cannabis and opioid overdoses: time to move on and examine potential mechanismsOle Rogeberg, Andreas Wahl Blomkvist, David Nutt
Pageof 18

Showing results (41-50 of 179) with videos related to

Sort By:
Pageof 18
Acta Neuropsychiatrica|March 8, 2019
Antidepressants; what's the beef?Guy M Goodwin, David Nutt
Lancet (London, England)|July 31, 2007
Seizures in a night clubLeslie A King, David Nutt
Journal of Psychopharmacology (Oxford, England)|October 26, 2018
THuNDRous news for human dopamine researchers: A selective dopamine D1 receptor antagonist will soon be available for clinical researchDavid Nutt, Trevor Robbins, Ann Hayes
Current Pharmaceutical Design|May 29, 2012
Neuroimaging of serotonin system in anxiety disordersEduard Maron, David Nutt, Jakov Shlik
Neuropharmacology|September 30, 2022
Psychedelics therapeutics: What we know, what we think, and what we need to researchDavid Nutt, Meg Spriggs, David Erritzoe
Neuropharmacology|November 13, 2012
Pharmacological cognitive enhancement in healthy people: potential and concernsSteve Hyman, Nora Volkow, David Nutt
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 11, 2014
The extinction of drugs for clinical research: Can the ECNP medicines chest save them?David Nutt, Gavin Kilpatrick, Ann Hayes
Frontiers in Psychiatry|April 6, 2019
A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted PsychotherapyBen Sessa, Laurie Higbed, David Nutt
Dialogues in Clinical Neuroscience|November 5, 2008
Sleep disorders as core symptoms of depressionDavid Nutt, Sue Wilson, Louise Paterson
Addiction (Abingdon, England)|June 9, 2018
Cannabis and opioid overdoses: time to move on and examine potential mechanismsOle Rogeberg, Andreas Wahl Blomkvist, David Nutt
Pageof 18